Cemex 1Q Net Profit Rises 13% on Year
By Anthony Harrup
MEXICO CITY--Mexican buildings materials company Cemex posted 13% higher net profit in the first quarter as revenue increased with higher prices offsetting lower sales volume in most markets.
Cemex reported on Thursday net profit of $254 million for the January-March quarter, or 17 cents an American depositary share, compared with $225 million in the first quarter of 2023.
Sales rose 3% to $4.14 billion thanks to higher prices.
Cement sales by volume were down 2% at 12 million metric tons, aggregates volume fell 2% to 31.6 million metric tons, and ready mix concrete volume dropped 12% to 10.3 million cubic meters. The company attributed the declines to fewer working days and bad weather in many markets, including in the U.S.
Cemex reported $772 million in earnings before interest, taxes, depreciation and amortization, up 5% from the year-earlier period and a record for a first quarter. Ebitda was supported by higher prices and lower cost inflation, as well as the company's growth investment strategy, Cemex said.
Write to Anthony Harrup at anthony.harrup@wsj.com
(END) Dow Jones Newswires
April 25, 2024 08:31 ET (12:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks